Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Regulatory News (FUM)

Share Price Information for Futura Medical (FUM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 39.00
Bid: 38.50
Ask: 38.75
Change: -0.575 (-1.47%)
Spread: 0.25 (0.649%)
Open: 39.05
High: 39.20
Low: 39.00
Prev. Close: 39.20
FUM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Manufacturing and Distribution Agreements with TTK

13 Jun 2016 07:00

RNS Number : 9244A
Futura Medical PLC
13 June 2016
 

For immediate release

13 June 2016

 

 

Futura Medical plc

("Futura" or the "Company")

 

Signs Manufacturing and Distribution Agreements with TTK

 

 

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, is pleased to announce that it has signed manufacturing and distribution agreements with TTK Protective Devices Limited ("TTK"), a pioneer in the condom business and part of the substantial Indian conglomerate TTK Group.

 

Under the terms of the manufacturing agreement, TTK will manufacture CSD500, Futura's novel erectogenic condom for supply worldwide. A regulatory filing has already been made with EU regulatory authorities to grant TTK the relevant authorisation to manufacture the product.

 

TTK will be one of two manufacturers of CSD500 as part of the Company's strategy to guarantee international supply. A European manufacturer already holds regulatory authorisation to manufacture the version of CSD500 currently marketed in the Netherlands and is awaiting regulatory authorisation for the extended shelf-life version of the product.

 

Futura has also signed an exclusive licensing agreement with TTK for the marketing and distribution of CSD500 in India for the lifetime of the patents. Futura will receive an upfront payment and royalties on product sales over the duration of the agreement.

 

TTK already owns the fastest growing condom brand in India, SKORE, which since its launch three years ago has achieved in excess of a 10% market share. TTK is attracted by the unique characteristics of CSD500 to further drive the growth of the SKORE brand. Subject to regulatory approval, CSD500 is expected to be launched by TTK in Q1 2017.

 

James Barder, Futura Medical's Chief Executive, said: "I am delighted to sign these two agreements for worldwide manufacturing and for distribution in India of our novel erectogenic condom, CSD500. It has always been our manufacturing strategy to offer CSD500's licensees the guarantee of supply by having dual sourced manufacture in Europe and in Asia. TTK is an ideal manufacturing partner as it is a highly experienced condom maker that has supplied the world's largest condom brands.

 

"I am also delighted to sign an exclusive agreement with TTK for the marketing and distribution of CSD500 in India. TTK's SKORE brand is the fastest growing condom brand in India and we look forward to CSD500 becoming a further growth driver in the SKORE franchise."

 

Mr T T Raghunathan, TTK Protective Device's Managing Director, said: "We are very pleased to be working with Futura Medical both in manufacturing CSD500 for worldwide supply and in distributing the product in India. TTK has always stood for innovation and quality in the global condom market, in which we have a long track record in manufacturing high quality condoms. We also look forward to the success of combining India's fastest growing condom brand, SKORE, with the innovation that CSD500 brings to condom users."

 

 

For further information please contact:

Futura Medical plc

James Barder, Chief Executive

Tel: +44 (0) 1483 685 670

Email to: james.barder@futuramedical.com

www.futuramedical.com

 

N+1 Singer (Nominated Adviser and Broker)

Aubrey Powell / Liz YongCorporate Finance

 

Tel:+44 (0) 20 7496 3000

For media enquiries please contact:

Buchanan

Mark Court / Sophie Cowles / Stephanie Watson

Tel: +44 (0) 20 7466 5000

 

 

Notes to Editors

 

Futura Medical plc

 

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

 

www.futuramedical.com

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRGGURUQUPQGQU
Date   Source Headline
30th Nov 20227:00 amRNSTotal Voting Rights
21st Oct 20224:40 pmRNSSecond Price Monitoring Extn
21st Oct 20224:35 pmRNSPrice Monitoring Extension
12th Oct 202212:25 pmRNSTR-1: Notification of major holdings
4th Oct 20225:31 pmRNSTotal Voting Rights
3rd Oct 20227:00 amRNSApplication to the US FDA for MED3000
16th Sep 20229:57 amRNSPDMR Dealing and Total Voting Rights
13th Sep 20227:00 amRNSFutura Medical Interim Results 2022
1st Sep 20227:00 amRNSNotice of Interim Results
31st Aug 20227:00 amRNSHighly positive FM71 Phase 3 Study Results
12th Jul 20224:41 pmRNSSecond Price Monitoring Extn
12th Jul 20224:35 pmRNSPrice Monitoring Extension
28th Jun 20223:58 pmRNSFutura Medical AGM Results
28th Jun 20227:00 amRNSFutura Medical AGM Statement
7th Jun 20221:33 pmRNSTR-1: Notification of major holdings
1st Jun 20227:00 amRNSNotice of AGM and Availability of Annual Report
31st May 20227:00 amRNSBlock Listing Six Monthly Return
24th May 202211:40 amRNSTR-1: Notification of major holdings
23rd May 202210:35 amRNSAgreement with Cooper Consumer Health - Correction
23rd May 20227:00 amRNSMED3000 Collaboration in EEA, UK & Switzerland
17th May 20223:56 pmRNSTR-1: Notification of major holdings
16th May 20222:51 pmRNSTR-1: Notification of major holdings
13th May 202212:12 pmRNSTR-1: Notification of major holdings
6th May 20224:41 pmRNSSecond Price Monitoring Extn
6th May 20224:35 pmRNSPrice Monitoring Extension
26th Apr 20227:00 amRNSFull Year Results 2021
14th Apr 20223:54 pmRNSFutura Medical Notice of Preliminary Results 2021
11th Apr 20224:28 pmRNSTR-1: Notification of major holdings
1st Apr 20224:58 pmRNSTR-1: Notification of major holdings
23rd Mar 20227:00 amRNSFutura Announces Collaboration with Menarini
2nd Feb 20225:30 pmRNSTR-1:Notification of major holdings
13th Jan 202210:32 amRNSRemuneration of Non-Executive Directors and TVR
20th Dec 20217:00 amRNSUS regulatory and commercial update for MED3000
2nd Dec 202112:02 pmRNSTR-1: Notification of major holdings
30th Nov 20217:00 amRNSBlock Listing Six Monthly Return
30th Nov 20217:00 amRNSFutura Medical plc Total Voting Rights
28th Oct 20217:00 amRNSFutura Medical plc Board Appointment
8th Oct 20217:00 amRNSFutura Medical plc Board Appointment
5th Oct 20214:05 pmRNSDirector/PDMR Shareholding
29th Sep 20217:00 amRNSInterim Results for Six Months ended 30 June 2021
27th Sep 20217:00 amRNSFutura Announces Collaboration with Labatec Pharma
17th Sep 20217:00 amRNSNotice of Interim Results
15th Sep 20217:00 amRNSFirst Patient visit in MED3000 Confirmatory Study
8th Sep 20213:49 pmRNSTR1: Notification of Major Holdings
31st Aug 20217:00 amRNSFutura Medical Announces Collaboration of MED3000
19th Jul 20217:00 amRNSFDA regulatory and commercial update for MED3000
28th Jun 20211:26 pmRNSResult of AGM
28th Jun 20217:00 amRNSAGM Statement
25th Jun 20212:55 pmRNSTR1: Notification of Major Holdings
15th Jun 20213:48 pmRNSTR-1: Notification of major holdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.